Candidiasis: a fungal infection--current challenges and progress in prevention and treatment

Area of Science:

• Mycology
• Infectious Diseases
• Immunology

Background:

• Candidiasis, primarily caused by Candida albicans, remains a prevalent fungal infection, manifesting as vulvovaginal candidiasis or mucocutaneous thrush.
• It commonly affects newborns, immunocompromised individuals (e.g., AIDS patients), and those on broad-spectrum antibiotics.
• While C. albicans is predominant, other species like C. tropicalis, C. glabrata, C. parapsilosis, and C. krusei are increasingly isolated.

Purpose of the Study:

• To review the current diagnosis, treatment, and prevention strategies for candidiasis.
• To highlight host defense mechanisms against candidiasis.
• To discuss advancements in diagnostic methods, the role of probiotics, and progress in vaccine development for candidiasis.

Main Methods:

• Literature review of current research on candidiasis diagnosis, treatment, and prevention.
• Focus on host-pathogen interactions and immune responses.
• Analysis of emerging therapeutic and prophylactic approaches, including probiotics and vaccines.

Main Results:

• Topical antifungals are effective for localized candidiasis; systemic chemotherapy is preferred for invasive disease.
• Probiotics and novel vaccine development represent advanced strategies for candidiasis prevention.
• Understanding host defense is crucial for managing and preventing candidiasis.

Conclusions:

• Effective management of candidiasis involves appropriate diagnosis and tailored treatment, balancing topical and systemic approaches.
• Future prevention strategies may rely on enhanced host defense, probiotics, and innovative vaccines.
• Continued research is essential to address challenges in candidiasis treatment and prevention, especially with emerging resistant strains.